Browse drugs

…thelial and endothelial barrier, resulting in pulmonary oedema. Baricitinib is a JAK1/2 inhibitor which inhibits inflammation in experiment…

…ty over 3 months compared with NSAIDs, with the improvement for baricitinib reaching statistical significance. Over 12 months, disease acti…

…numab 300 mg biweekly; and -44.15% (95% CI -50.44 to -37.86) vs baricitinib 2 mg diary. Statistically significant differences were found be…

…Background Janus kinase inhibitors (JAKi), like baricitinib, are used as monotherapy (MONO) and in combination with methotr…

…12 (10–60) 4.5 (0–80) 7.5 (0–10) 0 (0–10) 8.5 (3–10) 3.5 (0–10) Baricitinib 22 (21–40) 1 (0–18) 16 (5–40) 1 (0–10) 6 (0–1) 0 (0–1) 8 (0–5) …

… JAK inhibitors-related AERs extracted from the FAERS database. Baricitinib was associated with an elevated risk of cardiac disorders (ROR=…

…aricitinib (n=2), convalescent plasma (n=1), anakinra (n=1) and vilobelimab (n=1)). DISCERN (median (IQR)) reliability was 4 (IQR 3–4) and …

…oral small molecule kinase inhibitors, such as upadacitinib and deucravacitinib, as potential additions to standard of care in SLE, considering…

…tient was recently referred for consideration of treatment with baricitinib, a selective JAK1/JAK2 inhibitor. This case underscores the imp…

…steroids in children and highlighted safe use of agents such as baricitinib. Platform trials of the hyperinflammatory syndrome (paediatric …

…e Janus kinase inhibitors (JAKi), such as baricitinib (BAR) and tofacitinib (TOF), are oral therapeutic options for rheumatoid arthritis (R…

… two JAKi, and another 7% have received three. Drugs used were: upadacitinib (40%), baricitinib (35%), tofacitinib (24%), and filgotinib (11…